Search research articles
Contact Us
Filters
Showing results (51-60 of 98) with videos related to
Page
of 10
Sort By:
European Urology
|
May 20, 2025
Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial
Matthew D Galsky, Michiel S van der Heijden, Thomas Powles, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 13, 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
Martin Reck, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
JAMA Oncology
|
June 2, 2022
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial
Miguel Martin, Roberto Hegg, Sung-Bae Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 21, 2025
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1
Saadettin Kilickap, Ana Baramidze, Ahmet Sezer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2023
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649
Markus Moehler, Hong Xiao, Steven I Blum, et al.
Nature Medicine
|
March 7, 2025
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial
Kohei Shitara, Yelena Y Janjigian, Jaffer Ajani, et al.
The Lancet. Oncology
|
August 17, 2023
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial
Mustafa Özgüroğlu, Saadettin Kilickap, Ahmet Sezer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 11, 2024
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274
Matthew D Galsky, Johannes Alfred Witjes, Jürgen E Gschwend, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 6, 2024
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Solange Peters, Luis G Paz-Ares, Martin Reck, et al.
Cancer Treatment and Research Communications
|
December 13, 2025
Impact of patient and tumor characteristics on various aspects of the non-small cell lung cancer patient journey in Romania, Bulgaria, Serbia: A multicenter, non-interventional, retrospective cohort study
Alexandra C Preda, Rossitza Krasteva, Mihailo Stjepanović, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 98) with videos related to
Sort By:
Page
of 10
European Urology
|
May 20, 2025
Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial
Matthew D Galsky, Michiel S van der Heijden, Thomas Powles, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 13, 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
Martin Reck, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
JAMA Oncology
|
June 2, 2022
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial
Miguel Martin, Roberto Hegg, Sung-Bae Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 21, 2025
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1
Saadettin Kilickap, Ana Baramidze, Ahmet Sezer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2023
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649
Markus Moehler, Hong Xiao, Steven I Blum, et al.
Nature Medicine
|
March 7, 2025
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial
Kohei Shitara, Yelena Y Janjigian, Jaffer Ajani, et al.
The Lancet. Oncology
|
August 17, 2023
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial
Mustafa Özgüroğlu, Saadettin Kilickap, Ahmet Sezer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 11, 2024
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274
Matthew D Galsky, Johannes Alfred Witjes, Jürgen E Gschwend, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 6, 2024
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Solange Peters, Luis G Paz-Ares, Martin Reck, et al.
Cancer Treatment and Research Communications
|
December 13, 2025
Impact of patient and tumor characteristics on various aspects of the non-small cell lung cancer patient journey in Romania, Bulgaria, Serbia: A multicenter, non-interventional, retrospective cohort study
Alexandra C Preda, Rossitza Krasteva, Mihailo Stjepanović, et al.
Page
of 10